Merrill Lynch Upgrades PharMerica (PMC) to Buy
More News related to PMC
- PharMerica Names Geoffrey G. Meyers to Its Board of Directors
- UBS Starts Numerous Healthcare Stocks: CAH, MCK, ESRX at Buy, PMC, OCR at Neutral
- PharMerica to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
- PharMerica to Present at the Credit Suisse 18th Annual Healthcare Conference
- PharMerica to Present at the Oppenheimer 20th Annual Healthcare Conference
More News related to Upgrades
- Boenning & Scattergood Downgrades NutriSystem (NTRI) to Neutral
- Raymond James Upgrades Newpark Resources (NR) to Outperform
- Raymond James Upgrades Culp (CFI) to Strong Buy
- Satyam (SAY) Jumps 5% as JPMorgan Issues Intraday Upgrade
- Credit Suisse Upgrades MDC Holdings (MDC) to Neutral, $29 Target
Merrill Lynch upgrades PharMerica (NYSE: PMC) from Neutral to Buy.
PharMerica Corporation is an institutional pharmacy services company.
Related Categories
UpgradesStocks Mentioned
+0.19Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
